Clinical trials: Cirrhosis
Ascites, Liver Cirrhosis
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment…
- Trial name
- SPARe-1 (NCT00359437)
- Testing
- Satavaptan
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 501 people
- Sponsor
- Sanofi
Liver Cirrhosis
Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis
This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.
- Trial name
- NCT05106972
- Testing
- UC-MSC infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
Primary Biliary Cirrhosis
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or…
- Trial name
- NCT02955602
- Testing
- MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Gilead Sciences
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome
- Trial name
- NCT06417398
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Cirrhosis
Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects
The disposition of NRL972 after a 15-second intravenous injection of 2 mg NRL972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects.
- Trial name
- NCT01164332
- Testing
- NRL972
- Where
- Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Norgine
Liver Cirrhosis
Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients
The objective of this study is to evaluate the correlation of the calculated portosystemic pressure gradient (PPG) obtained by direct portal and hepatic pressure measurements with the EchoTip® Insight™ and indirect portal vein…
- Trial name
- NCT04987034
- Testing
- EchoTip® Insight™
- Where
- 3 sites in Belgium, Netherlands and 1 more
- Volunteers
- 35 people
- Sponsor
- Cook Research Incorporated
Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD)
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe…
- Conditions
- Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 1 (NCT03486899)
- Testing
- BMS-986036
- Where
- 89 sites in United States, Japan
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Liver Cirrhosis, Chronic Hepatitis C
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
This study evaluated the clinical response of the efficacy and safety of the combination therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free group in CHC patients with compensated LC.
- Trial name
- NCT00304551
- Testing
- peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin
- Where
- 8 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Chugai Pharmaceutical
Hepatocellular Carcinoma, Cirrhosis
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy.
- Trial name
- LIVERATION (NCT05201404)
- Testing
- Namodenoson
- Where
- 32 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 471 people
- Sponsor
- Can-Fite BioPharma
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Liver Cirrhosis
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects…
- Trial name
- NCT01904409
- Testing
- Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet
- Where
- 120 sites in United States, Russia
- Volunteers
- 420 people
- Sponsor
- Bausch Health Americas, Inc.
Hepatitis B
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem…
- Trial name
- NCT03826433
- Testing
- Peripheral iv
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Hepatitis C Virus
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based…
- Trial name
- GIFT-II (NCT02023112)
- Testing
- ABT-450/r/ABT-267, Ribavirin
- Volunteers
- 171 people
- Sponsor
- AbbVie
Liver Cirrhosis, Hepatitis C, Chronic
Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
Study to assess the antiviral efficacy, pharmacokinetics, and tolerability of 200 mg BILN 2061 ZW in a polyethylene glycol 400 (PEG 400: ethanol) drinking solution given orally for two days bid to patients with cirrhosis and…
- Trial name
- NCT02226939
- Testing
- BILN 2061 ZW
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Hepatic Cirrhosis
Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
This is a multi-centre, multi-national, open study to assess the pharmacokinetics of NRL972 in patients with hepatic cirrhosis CTP-classes A, B, and C (histologically confirmed by liver biopsy).
- Trial name
- NCT00794482
- Testing
- NRL972
- Where
- Germany
- Volunteers
- 1,200 people
- Sponsor
- Norgine
Liver Diseases, Liver Cirrhosis
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
Early screening and monitoring of chronic liver diseases in hepatology practice has become crucial. To achieve this goal, hepatology clinics need simple and available tools at the point-of-care to perform disease severity…
- Conditions
- Liver Diseases, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- DIACEPA (NCT04782050)
- Testing
- Ultrasound liver assessment
- Where
- France
- Volunteers
- 100 people
- Sponsor
- E-Scopics
Carcinoma, Hepatocellular, Cirrhosis, Liver
Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance testing for the early detection of Hepatocellular Carcinoma (HCC).
- Trial name
- NCT03878550
- Where
- 20 sites in United States, Israel
- Volunteers
- 766 people
- Sponsor
- Glycotest, Inc.
Hepatic Cirrhosis
Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.
- Trial name
- NCT00857480
- Testing
- NRL972
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Norgine
Cirrhosis, Liver, Refractory Ascites
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
This is a single centre, prospective, uncontrolled study to include 12 consecutive patients with cirrhosis of the liver and recurrent or refractory ascites.
- Trial name
- NCT01438970
- Testing
- ALFApump system
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Sequana Medical N.V.
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.